Supporting Information:

Organocatalytic Stereocontrolled Synthesis of 3,3'- Pyrrolidinyl Spirooxindoles by [3+2] Annulation of Isocyanoesters with Methyleneindolinones

Liang-Liang Wang,^{†,‡} Jian-Fei Bai,^{†,‡} Lin Peng,^{†,‡} Liang-Wen Qi,^{†,‡} Li-Na Jia,^{†,‡} Yun-Long Guo,^{†,‡} Xi-Ya Luo,^{†,‡} Xiao-Ying Xu,^{*,†} and Li-Xin Wang^{*,†}

[†]Key Laboratory of Asymmetric Synthesis and Chirotechnology of Sichuan Province, Chengdu Institute of Organic Chemistry, Chinese Academy of Sciences, Chengdu 610041, China; [‡] Graduate University of Chinese Academy of Science, Beijing, China. E-mail: wlxioc@cioc.ac.cn; xuxy@cioc.ac.cn.

Table of Contents

1. General methods	S2
2. Typical procedure for asymmetric [3+2] cycloaddition reaction	
with N-phenyl amide protected methyleneindolinones	S2
3. Synthesis of 7 and 8	S7
4. Typical procedure for asymmetric [3+2] cycloaddition reaction	
With N-Boc protected methyleneindolinones	S9
5. Depretection of [3+2] cycloadduct	S13
6. Controlled syntheses of enantio- and diastereomers	S14
7. Control experiment for testing the effect of N-protecting group on	
the diasteroselectivity and proposed mechanism.	S15
8. Crystal data for 7, 5m and 5p	S18
9. NMR spectra	S22
10. Crude NMR spectra of some reaction mixtures	S 60
11. HPLC chromatograms	S72

1. General methods

Commercial grade solvent was dried and purified by standard procedures as specified in Purification of Laboratory Chemicals, 4th Ed (Armarego, W. L. F.; Perrin, D. D. Butterworth Heinemann: 1997). NMR spectra were recorded with tetramethylsilane as the internal standard. ¹H NMR spectra were recorded at 300 MHz, and ¹³C NMR spectra were recorded at 75 MHz (Bruker Avance). ¹H NMR chemical shifts (δ) are reported in ppm relative to tetramethylsilane (TMS) with the solvent signal as the internal standard (CDCl₃ at 7.26 ppm, (CD₃)₂SO at 2.50 ppm). ¹³C NMR chemical shifts are reported in ppm from tetramethylsilane (TMS) with the solvent resonance as the internal standard (CDCl₃ at 77.00 ppm, (CD₃)₂SO at 39.52 ppm). Data are given as: s (singlet), d (doublet), t (triplet), q (quartet), dd (double of doublet) or m (multiplets), coupling constants (Hz) and integration. Flash column chromatography was carried out using silica gel eluting with ethyl acetate and petroleum ether. Highresolution mass spectra were obtained with the Q-TOF-Premier mass spectrometer. Reactions were monitored by TLC and visualized with ultraviolet light. Enantiomeric excess was determined by HPLC analysis on chiralpak AD-H, or OD-H columns. IR spectra were recorded on a ThermoFisher Nicolet Avatar 360 FTIR spectrometer on a KBr beamsplitter. Optical rotations are reported as follows: $\left[\alpha\right]^{20}$ (C in g/per 100 mL, DCM).

2. Typical Procedure for the Asymmetric [3+2] Cycloaddition

Reaction with N-phenyl amide protected Methyleneindolinones

All starting materials were purchased from commercial supplier and used without further purification. Substrates **3**, **4** were prepared according to literature methods,¹ purified by chromatography.

(a) B. Tan, N. R. Candeias and C. F. Barbas III., J. Am. Chem. Soc., 2011, 133, 4672; (b) J. Song, C. Guo, P. H. Chen, J. Yu, S. W. Luo and L. Z. Gong, Chem. Eur. J., 2011, 17, 7786.



Typical Procedure for synthesis of 5a-l: Methyleneindolinones **3** (0.2 mmol) and Isocyanoesters **4** (0.3 mmol) were dissolved in 1.0 mL CHCl₃, and 4 Å MS (200 mg) was added. When the mixture was cooled to -20 °C, catalyst **2a** (10 % mmol) was added. After stirred for the indicated time, the reaction mixture was directly subjected

to flash column chromatography on silica gel (petroleum ether/ethyl acetate) to afford the corresponding pure products **5**.

(3R, 4'S, 5'R)-4'-ethyl 5'-methyl 2-oxo-5'-phenyl-1-(phenylcarbamoyl)-4',5' dihydrospiro[indoline-3,3'-pyrrole]-4',5'-dicarboxylate (5a)

White solid, $[\alpha]_D^{20} = -132.8$ (*c* 1.16, DCM), 60 % yield, 2.7:1 dr, 95 % ee; HPLC: Chiralcel AD-H column, hexane/i-PrOH = 85/15, flow rate 1.0 mL/min, UV detection at 220 nm, $t_{major} = 23.3$ min, $t_{minor} = 25.7$ min; ¹H NMR (CDCl₃, 300 MHz) δ 0.78 (t, J = 7.1 Hz, 3H), 3.55-3.67 (m, 2H), 3.83 (s, 3H), 4.83 (s, 1H), 7.11-7.19 (m, 3H), 7.34-7.37 (m, 6H), 7.51-7.57 (m, 3H), 7.63-7.66 (m, 2H), 8.35 (d, J = 8.3 Hz, 1H), 10.30 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 13.4, 53.5, 59.9, 60.8, 69.4, 89.4, 116.6, 120.7, 122.4, 124.8, 125.0, 126.1, 126.3, 128.2 (2C), 129.0, 130.4, 136.5, 138.3, 140.9, 148.4, 161.8, 166.8, 171.8, 176.0; HRMS (ESI) Calcd. For C29H25N3O6 [M+Na]⁺: 534.1636, Found: 524.1641; IR (KBr) v 3253.3, 1736.1, 1599.0, 1552.9, 1447.8, 1242.0, 1166.0, 1022.8, 759.6, 694.4 cm⁻¹.

(3R,4'S,5'S)-diethyl 2-oxo-5'-phenyl-1-(phenylcarbamoyl)-4',5'-dihydrospiro-[indoline-3,3'-pyrrole]-4',5'-dicarboxylate (5a')



¹H NMR (CDCl₃, 300 MHz) δ 0.72 (t, *J* = 7.1 Hz, 3H), 3.76-3.92 (m, 5H), 4.21 (s, 1H), 7.15 (t, *J* = 7.5 Hz, 1H), 7.24-7.29 (m, 1H), 7.33-7.45 (m, 7H), 7.54 (d, *J* = 8.3 Hz, 2H), 7.61-7.63 (m, 2H), 7.82 (d, *J* = 7.7 Hz, 1H), 8.39 (d, *J* = 8.2 Hz, 1H), 10.43 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 13.3, 53.4, 61.5, 62.9, 70.9, 88.0, 116.5, 120.5, 123.7, 124.8,

125.6, 126.3, 126.8, 127.9, 128.3, 129.1, 130.1, 136.7, 140.4, 141.8, 148.6, 161.1, 167.8, 171.0, 177.5; HRMS (ESI) Calcd. for C29H25N3O6 [M+Na]⁺: 534.1636, Found: 534.1641;

(3R,4'S,5'R)-4'-ethyl 5'-methyl 5-fluoro- 2-oxo- 5'-phenyl-1 -(phenylcarbamoyl) - 4',5' - dihydrospiro[indoline-3,3'-pyrrole]-4',5'-dicarboxylate (5b)

2H), 7.36-7.40 (m, 5H), 7.52-7.56 (m, 3H), 7.63 (d, J = 7.4 Hz, 2H), 8.34-8.37 (m, 1H), 10.24 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 13.5, 53.7, 60.1, 61.2, 69.4, 89.7, 114.1 (d, J = 26.1 Hz, 1C), 117.1 (d, J = 22.5 Hz, 1C), 118.0 (d, J = 7.7 Hz, 1C), 120.5, 120.9, 125.1, 126.3, 128.4, 128.5, 129.2, 136.4, 136.9, 138.2, 148.4, 159.9 (d, J = 243.7 Hz, 1C), 161.3, 166.8, 171.7, 175.7; HRMS (ESI) Calcd. for C29H24FN3O6

 $[M+H]^+$: 530.1722, Found: 530.1712; IR (KBr) v 3254.0, 1736.5, 1600.4, 1555.5, 1481.1, 1447.9, 1292.4, 1240.9, 1160.7, 754.9 cm⁻¹.

(3R,4'S,5'R)-4'-ethyl 5'-methyl 5-chloro-2-oxo-5'-phenyl-1-(phenylcarbamoyl) - 4',5'-dihydrospiro[indoline-3,3'-pyrrole]-4',5'-dicarboxylate (5c)

(3R,4'S,5'R)-4'-ethyl 5'-methyl 5-bromo-2-oxo-5'-phenyl- 1-(phenylcarbamoyl) - 4',5'-dihydrospiro[indoline-3,3'-pyrrole]-4',5'-dicarboxylate (5d)

^{Ph, COOMe} ^{Br, N} ^{Br, N} ^{CONHPh} ^{CONHPh} ^{White solid, $[\alpha]_D^{20} = -96.6$ (*c* 1.36, DCM), 64 % yield, 8.0:1 dr, 94 % ee; HPLC: Chiralcel AD-H column, hexane/i-PrOH = 85/15, flow rate 1.0 mL/min, UV detection at 220 nm, $t_{major} = 33.5$ min, $t_{minor} = 24.1$ min; ¹H NMR (DMSO, 300 MHz) δ 0.77 (t, J = 7.1 Hz, 3H), 3.53-3.59 (m, 2H), 3.71 (s, 3H), 4.80 (s, 1H), 7.12 (s, 1H), 7.18 (d, J = 7.4 Hz, 1H), 7.36-7.49 (m, 7H), 7.59-7.66 (m, 3H), 7.82 (s, 1H), 7.93 (d, J = 8.7 Hz, 1H), 10.29 (s, 1H); ¹³C NMR (DMSO, 75 MHz) δ 13.2, 53.1, 59.5, 60.5, 68.6, 89.0, 116.0, 116.8, 120.2, 124.5, 125.4, 126.2, 128.2, 128.2, 129.0, 129.1, 132.5, 136.9, 138.6, 140.2, 147.8, 163.1, 166.9, 171.2, 174.0; HRMS (ESI) Calcd. for C29H24BrN3O6 [M+H]⁺: 590.0929, Found: 590.0910; IR (KBr) v 3248.0, 1733.4, 1600.5, 1557.0, 1463.8, 1293.4, 1239.5, 1164.8, 756.1, 691.6 cm⁻¹.}

(3R,4'S,5'R)-4'-ethyl 5'-methyl 5-methyl-2-oxo-5'-phenyl- 1- (phenylcarbamoyl) - 4',5'-dihydrospiro[indoline-3,3'-pyrrole]-4',5'-dicarboxylate (5e)



White solid, $[\alpha]_D^{20} = -132.7$ (*c* 1.10, DCM), 61 % yield, 7.2:1 dr, 97 % ee; HPLC: Chiralcel AD-H column, hexane/i-PrOH = 85/15, flow rate 1.0 mL/min, UV detection at 220 nm, $t_{major} = 24.7$ min, $t_{minor} = 20.7$ min; ¹H NMR (CDCl₃, 300 MHz) δ 0.79 (t, J = 7.11 Hz,

3H), 2.25(s, 3H), 3.57-3.72 (m, 2H), 3.84 (s, 3H), 4.80 (s, 1H), 6.99 (s, 1H), 7.15-7.22 (m, 2H), 7.34-7.40 (m, 5H), 7.52-7.57 (m, 3H), 7.66 (d, J = 6.9 Hz, 2H), 8.22 (d, J = 8.3 Hz, 1H), 10.30 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 13.5, 20.9, 53.6, 60.1, 60.9, 69.5, 89.4, 116.4, 120.8, 122.4, 124.9, 126.3, 126.7, 128.2, 128.3, 128.6, 129.1, 130.9,

134.9, 136.6, 138.6, 148.6, 162.1, 167.0, 171.9, 176.1; HRMS (ESI) Calcd. for C30 H27N3O6 [M+H]⁺: 526.1973, Found: 526.1970; IR (KBr) *v* 3252.3, 1735.7, 1598.7, 1555.7, 1487.8, 1447.8, 1307.9, 1158.1, 755.3, 695.1 cm⁻¹.

(3R,4'S,5'R)-4'-ethyl 5'-methyl 6-chloro-2-oxo-5'-phenyl-1-(phenylcarbamoyl) - 4',5'-dihydrospiro[indoline-3,3'-pyrrole]-4',5'-dicarboxylate (5f)



White solid, $[\alpha]_D^{20} = -132.4$ (*c* 0.48, DCM), 53 % yield, 5.1:1 dr, 92 % ee; HPLC: Chiralcel AD-H column, hexane/i-PrOH = 85/15, flow rate 1.0 mL/min, UV detection at 220 nm, $t_{major} = 18.6$ min, $t_{minor} = 21.8$ min; ¹H NMR (CDCl₃, 300 MHz) δ 0.84 (t, J = 7.1, 3H), 3.57-3.68 (m, 2H), 3.84 (s, 3H), 4.81 (s, 1H), 7.12 (s, 2H), 7.17-7.22

(m, 1H), 7.32-7.42 (m, 5H), 7.50 (s, 1H), 7.56 (d, J = 8.0 Hz, 2H), 7.62 (d, J = 6.9 Hz, 2H), 8.45 (s, 1H), 10.23 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 13.5, 53.6, 60.0, 61.1, 69.2, 89.7, 117.4, 120.9, 125.1, 125.2, 126.4, 127.3, 128.4, 128.5, 129.2, 136.3, 136.6, 138.2, 141.7, 148.2, 161.3, 166.9, 171.7, 176.0 (one carbon missing); HRMS (ESI) Calcd. for C29 H24ClN3O6 [M+H]⁺: 546.1426, Found: 546.1422; IR (KBr) v 3258.5, 1738.3, 1598.4, 1553.0, 1448.0, 1287.9, 1165.3, 1023.6, 756.1, 694.7 cm⁻¹.

(3R,4'S,5'R)-4'-ethyl 5'-methyl 6-bromo-2-oxo-5'-phenyl-1-(phenylcarbamoyl) - 4',5'-dihydrospiro[indoline-3,3'-pyrrole]-4',5'-dicarboxylate (5g)



White solid, $[\alpha]_D^{20} = -100.3$ (*c* 0.51, DCM), 50 % yield, 3.9:1 dr, 90 % ee; HPLC: Chiralcel AD-H column, hexane/i-PrOH = 85/15, flow rate 1.0 mL/min, UV detection at 220 nm, $t_{major} = 18.3$ min, $t_{minor} = 21.9$ min; ¹H NMR (CDCl₃, 300 MHz) δ 0.84 (t, J = 7.1 Hz, 3H), 3.58-3.70 (m, 2H), 3.84 (s, 3H), 4.81(s, 1H), 7.06 (d, J = 8.3

Hz, 1H), 7.19-7.29 (m, 2H), 7,37-7.42 (m, 5H), 7.50 (s, 1H), 7.55 (d, J = 7.6 Hz, 2H), 7.60-7.63 (m, 2H), 8.61 (s, 1H), 10.22 (1H); ¹³C NMR (CDCl₃, 75 MHz) δ 13.5, 53.7, 60.0, 61.2, 69.2, 89.7, 120.2, 120.9, 121.3, 124.6, 125.2, 126.3, 127.6, 128.2, 128.4, 128.5, 129.2, 136.3, 138.1, 141.8, 148.2, 161.3, 166.9, 171.7, 175.8; HRMS (ESI) Calcd. for C29H24BrN3O6 [M+H]⁺: 590.0921, Found: 590.0911; IR (KBr) *v* 3250.5, 1739.2, 1682.5, 1597.4, 1552.3, 1447.9, 1287.6, 1160.4, 754.2, 694.2 cm⁻¹.

(3R,4'S,5'R)-4'-benzyl 5'-methyl 2-oxo-5'-phenyl-1-(phenylcarbamoyl) -4',5'dihydrospiro-[indoline-3,3'-pyrrole]-4',5'-dicarboxylate (5h)



CONHPh

White solid, $[\alpha]_D^{20} = -149.7$ (*c* 0.88, DCM), 45 % yield, 3.2:1 dr, 95 % ee; HPLC: Chiralcel AD-H column, hexane/i-PrOH = 85/15, flow rate 1.0 mL/min, UV detection at 220 nm, $t_{major} = 49.7$ min, $t_{minor} = 42.9$ min; ¹H NMR (CDCl₃, 300 MHz) δ 3.84 (s, 3H), 4.45 (d,

J = 12.0 Hz, 1H), 4.63 (d, J = 12.0 Hz, 1H), 4.90 (s, 1H), 6.91-6.94 (m, 2H), 6.99-7.05 (m, 1H), 7.10-7.13 (m, 1H), 7.16-7.23 (m, 5H), 7.34-7.41 (m, 6H), 7.52-7.57 (m, 2H), 7.61-7.63 (m, 2H), 8.34 (d, J = 8.2 Hz, 1H), 10.28 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 53.6, 59.9, 66.9, 69.5, 89.6, 116.8, 120.9, 122.3, 124.9, 125.1, 126.3, 126.4, 128.3, 128.4, 128.5, 128.9, 129.0, 129.1, 130.5, 134.4, 136.6, 138.3, 140.9, 148.5, 161.8, 166.8, 171.8, 176.1; HRMS (ESI) Calcd. for C34H27N3O6 [M+H]⁺: 547.1973,Found: 574.1971; IR (KBr) *v* 3253.1, 1731.9, 1598.8, 1477.1, 1464.1, 1447.8, 1259.9, 1166.8, 757.7, 695.6 cm⁻¹.

(3R,4'S,5'R)-4'-tert-butyl 5'-methyl 2-oxo-5'-phenyl-1-(phenylcarbamoyl) -4',5'dihydrospiro[indoline-3,3'-pyrrole]-4',5'-dicarboxylate (5i)



White solid, $[\alpha]_D^{20} = -131.0$ (*c* 0.75, DCM), 41 % yield, 2.8:1 dr, 96 % ee; HPLC: Chiralcel OD-H column, hexane/i-PrOH = 85/15, flow rate 1.0 mL/min, UV detection at 220 nm, $t_{major} = 9.2$ min, $t_{minor} = 18.6$ min; ¹H NMR (CDCl₃, 300 MHz) δ 0.96 (s, 9H), 3.84 (s,

3H), 4.69 (s, 1H), 7.10 (t, J = 7.6 Hz, 1H), 7.18 (t, J = 7.5 Hz, 1H), 7.25 (s, 1H), 7.34-7.44 (m, 6H), 7.55-7.59 (m, 3H), 7.68 (d, J = 7.2 Hz, 2H), 8.37 (d, J = 8.3 Hz, 1H), 10.34 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 27.3, 53.5, 60.4, 69.6, 82.5, 89.3, 116.6, 120.9, 122.5, 124.9, 125.0, 126.8, 127.0, 128.2, 128.3, 129.1, 130.4, 136.6, 138.3, 141.0, 148.7, 162.0, 166.0, 172.1, 176.4; HRMS (ESI) Calcd. for C31H29N3O6 [M+H]⁺: 540.2129, Found: 540.2111; IR (KBr) ν 3251.7, 1737.9, 1599.1, 1555.6, 1477.8, 1464.8, 1311.0, 1278.0, 758.2, 694.5 cm⁻¹.

(3R,4'S,5'R)-diethyl 2-oxo-5'-phenyl- 1-(phenylcarbamoyl)-4',5'- dihydrospiro [indoline-3,3'-pyrrole]-4',5'-dicarboxylate (5j)

^{Ph, COOEt} White solid, $[\alpha]_D^{20} = -149.5$ (*c* 0.79, DCM), 41 % yield, 3.0:1 dr, 96 % ee; HPLC: Chiralcel AD-H column, hexane/i-PrOH = 85/15, flow rate 1.0 mL/min, UV detection at 220 nm, $t_{major} = 18.2$ min, t_{minor} = 20.5 min; ¹H NMR (CDCl₃, 300 MHz) δ 0.78 (t, J = 7.1 Hz, 3H), 1.29(t, J = 7.1 Hz, 3H), 3.59-3.65 (m, 2H), 4.29-4.36 (m, 2H), 4.84 (s, 1H), 7.09-7.20 (m, 3H), 7.34-7.43 (m, 6H), 7.53-7.58 (m, 3H), 7.63 (d, J = 7.0 Hz, 2H), 8.37 (d, J =8.2 Hz, 1H), 10.35 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 13.5, 13.9, 59.8, 60.9, 62.6, 69.5, 89.6, 116.7, 120.7, 122.5, 124.9, 125.1, 126.3, 126.4, 128.3, 128.6, 129.1, 130.5, 136.6, 138.5, 140.9, 148.6, 161.7, 167.0, 171.2, 176.2; HRMS (ESI) Calcd. for C30H27N3O6 [M+Na]⁺: 548.1792, Found: 548.1794; IR (KBr) v 3252.9, 1736.6, 1599.0, 1555.5, 1464.5, 1310.4, 1278.1, 1166.4, 760.3, 694.2 cm⁻¹.

(3R,4'S,5'R)-diethyl-5-bromo-2-oxo-5'-phenyl-1-(phenylcarbamoyl)-4',5'- dihydr -ospiro-[indoline-3,3'-pyrrole]-4',5'-dicarboxylate (5k)

White solid, $[\alpha]_D^{20} = -70.5$ (*c* 1.08, DCM), 50 % yield, 5.6:1 dr, 94 % ee; HPLC: Chiralcel AD-H column, hexane/i-PrOH = 85/15, flow rate 1.0 mL/min, UV detection at 220 nm, $t_{major} = 26.7$ min, $t_{minor} = 21.6$ min; ¹H NMR (CDCl₃, 300 MHz) δ 0.83 (t, J = 7.0 Hz, 3H), 1.22-1.34 (m, 3H), 3.64 (t, J = 6.1 Hz, 2H), 4.31 (t, J = 7.2 Hz, 2H), 4.83 (s, 1H), 7.18 (t, J = 7.3 Hz, 1H), 7.35-7.40 (m, 6H), 7.53 (d, J = 8.8 Hz, 4H), 7.63 (d, J = 6.8 Hz, 2H), 8.26 (d, J = 8.7 Hz,1H), 10.24 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 13.5, 13.9, 60.2, 61.2, 62.7, 69.1, 89.8, 118.1, 118.2 120.8, 124.6, 125.1, 126.3, 127.4, 128.3, 129.2, 129.4, 133.4, 136.4, 138.5, 139.9, 148.3, 160.8, 166.9, 171.0, 175.5; HRMS (ESI) Calcd. for C30H26Br3NO6 [M+Na]⁺ 626.0897, Found: 626.0906; IR (KBr) v 3249.3, 1738.2, 1559.0, 1552.5, 1470.0, 1447.9, 1292.9, 1240.8, 754.7, 694.7 cm⁻¹.

(3R,4'S,5'R)-diethyl 5-methyl-2-oxo-5'-phenyl-1-(phenylcarbamoyl)-4',5'dihydro -spiro[indoline-3,3'-pyrrole]-4',5'-dicarboxylate (5l)

Ph, COOEt V EtOOC /// N Me O fl CONHPh

White solid, $[\alpha]_D^{20} = -108.8$ (*c* 0.92, DCM), 54 % yield, 3.0:1 dr, 95 % ee; HPLC: Chiralcel AD-H column, hexane/i-PrOH = 85/15, flow rate 1.0 mL/min, UV detection at 220 nm, $t_{major} = 21.5$ min, $t_{minor} = 17.9$ min; ¹H NMR (CDCl₃, 300 MHz) δ 0.78 (t, J = 7.1 Hz,

3H), 1.29 (t, J = 7.2 Hz, 3H), 2.25 (s, 3H), 3.59-3.63 (m, 2H), 4.27-4.36 (m, 2H), 4.81 (s, 1H), 6.99 (s, 1H), 7.15-7.22 (m, 2H), 7.36-7.40 (m, 5H), 7.52-7.57 (m, 3H), 7.65 (d, J = 7.2 Hz, 2H), 8.22 (d, J = 8.5 Hz, 1H), 10.34 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 13.5, 13.9, 20.9, 60.0, 60.9, 62.6, 69.5, 89.5, 116.4, 120.7, 122.5, 124.8, 126.4, 126.8, 128.1, 128.2, 129.1, 130.9, 134.9, 136.7, 138.5, 138.7, 148.6, 161.8, 167.0, 171.2, 176.2; HRMS (ESI) Calcd. for C31H29N3O6 [M+Na]⁺: 562.1949, Found: 562.1949; IR (KBr) *v* 3249.6, 1732.1, 1598.9, 1556.2, 1487.3, 1447.7, 1297.9, 1180.8, 754.4, 695.2 cm⁻¹.

3. Synhesis of 7 and 8



Procedure for reduction and deprotection of 5c:

To a solution of **5c** (80 mg, 92 % ee) in DMF (3.0 mL) charged with N_2 at -5 °C, HSiCl₃ (0.3 mL) was added. After stirred overnight, the reaction mixture was poured into saturated NaHCO₃ aq. and stirred for another 0.5 h at room temperature, then extracted with CH₂Cl₂. Organic layer was dried over anhydrous Na₂SO₄, concentrated under vacuum and purified by flash column chromatography on silica gel to give the white solid **6** in 75 % yield, 85 % ee.

To a solution of **6** (60 mg) in THF (3 mL), KOH (103 mg) and silica gel (366 mg) were added, the reaction mixture was stirred at 60 $^{\circ}$ C for 2 h, then evaporated the solvent and purified by flash column chromatography on silica gel to give the white solid **7** in 70 % yield, 85 % ee.

(3R,4'S,5'R)-4'-ethyl 5'-methyl 5-chloro-2-oxo-5'-phenylspiro[indoline- 3,3'pyrrolidine]- 4',5'-dicarboxylate (7)

Ph. COOME HPLC: Chiralcel AD-H column, hexane/i-PrOH = 85/15, flow rate 1.0 mL/min, UV detection at 220 nm, $t_{major} = 8.4$ min, $t_{minor} = 7.3$ min; ¹H NMR (CDCl₃, 300 MHz) δ 0.85 (t, J = 7.1 Hz, 3H), 3.55 (d, J = 11.5 Hz, 1H), 3.61-3.73 (m, 3H), 3.79 (s, 3H), 4.47 (s, 1H), 6.81 (d, J = 8.8 Hz, 1H), 7.18 (d, J = 6.2 Hz, 2H), 7.24-7.35 (m, 3H), 7.70 (d, J = 7.1 Hz, 2H), 8.56 (s, 1H);¹³C NMR (DMSO, 75 MHz) δ 13.2, 52.9, 55.6, 57.1, 60.0, 60.3, 75.9, 110.8, 125.0, 125.3, 126.2, 127.5, 127.9, 128.3, 130.5, 140.0, 141.1, 168.2, 173.5, 178.8; HRMS (ESI) Calcd. for C22H21CIN2O5 [M+Na]⁺: 429.1212, Found: 429.1200.

Procedure for synthesis of 8:



To a solution of **5c** (43 mg, 92 % ee) in THF (1.0 mL), concentrated HCl (1.0 mL) was added and stirred at room temperature for 20 h, then the reaction mixture were poured into saturated NaHCO₃ aq. and stirred for another 0.5 h at room temperature, extracted with CH_2Cl_2 . Organic layer was dried over anhydrous Na_2SO_4 , concentrated under vacuum and purified by flash column chromatography on silica gel to give the white solid **8** in 70% yield, 82 % ee.

(2R,3S)-4-ethyl 1-methyl 2-amino-3- (5-chloro- 2-oxo -1- (phenylcarbamoyl) - 2,3,3a,7a-tetrahydro-1H-indol-3-yl)-2-phenylsuccinate (8)

4. Typical Procedure for [3+2] Cycloaddition Reaction with N-Boc

protected Methyleneindolinones $R^{2}OOC$, R^{1} , $R^{2}OOC$, R^{1} , $R^{2}OOC$, R^{3} , $R^{3}OOC$, Ph, $R^{2}OOC$, R^{1} , , R^{1}

Typical Procedure for synthesis of 5m-y: Methyleneindolinones **3** (0.2 mmol) and Isocyanoesters **4** (0.22 mmol) were dissolved in 1.0 mL CHCl₃, and 4 Å MS (200 mg) was added. When the mixture was cooled to -20 °C, catalyst **2a** (10% mmol) was added. After stirred for the indicated time, the reaction mixture was directly subjected to flash column chromatography on silica gel (petroleum ether/ethyl acetate) to afford the corresponding pure products **5**.

(3R,4'S,5'S)-1-tert-butyl 4'-ethyl 5'-methyl 2-oxo-5'-phenyl-4',5'-dihydrospiro [indoline-3,3'-pyrrole]-1,4',5'-tricarboxylate (5m)



White solid, $[\alpha]_D^{20} = -10.6$ (*c* 0.68, DCM), 53 % yield, 3.0:1 dr, 99 % ee; HPLC: Chiralcel AD-H column, hexane/i-PrOH = 85/15, flow rate 1.0 mL/min, UV detection at 220 nm, $t_{major} = 5.6$ min, $t_{minor} = 6.8$ min; ¹H NMR (CDCl₃, 300 MHz) δ 0.73 (t, J = 7.1 Hz, 3H), 1.62 (s, 9H),

3.75-3.88 (m, 5H), 4.19 (s, 1H), 7.21-7.23 (m, 1H), 7.31-7.42 (m, 5H), 7.56-7.59 (m, 2H), 7.76 (d, J = 7.7 Hz, 1H), 7.93 (d, J = 8.1 Hz, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 13.3, 28.0, 53.3, 61.2 62.7, 70.3, 85.1, 87.7, 114.9, 123.8, 125.1, 126.5, 126.8, 127.8, 128.2, 129.7, 139.9, 141.7, 148.7, 161.8, 168.1, 171.3, 173.1; HRMS (ESI) Calcd. for C27H28N2O7 [M+H]⁺: 493.1969, Found: 493.1971; IR (KBr) v 3444.1, 2983.8, 1761.7, 1735.6, 1347.3, 1293.2, 1260.4, 1147.1, 1007.0, 780.4 cm⁻¹.

(3R,4'S,5'R)-1-tert-butyl 4'-ethyl 5'-methyl 2-oxo-5'-phenyl-4',5'-dihydrospiro [indoline-3,3'-pyrrole]-1,4',5'-tricarboxylate (5m')

Ph, COOMe ¹H NMR (CDCl₃, 300 MHz) δ 0.77 (t, J = 7.1 Hz, 3H), 1.65 (s, 9H), EtOOC N N 3.53-3.62 (m, 2H), 3.80 (s, 3H), 4.78 (s, 1H), 7.05-7.11 (m, 2H), N 7.33-7.37 (m, 4H), 7.48 (s, 1H), 7.62-7.65 (m, 2H), 7.86 (d, J = 8.3Hz, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 13.4, 28.0, 53.5, 60.1, 60.7, 68.8, 85.3, 89.1, 115.1, 122.5, 124.6, 126.4, 126.5, 128.1, 128.2, 130.1, 138.6, 140.4,

148.5, 162.5, 167.2, 171.5, 171.8.

(3R,4'S,5'S)-1-tert-butyl 4'-ethyl 5'-methyl 5-fluoro-2-oxo-5'-phenyl -4',5'dihydrospiro[indoline-3,3'-pyrrole]-1,4',5'-tricarboxylate (5n)



MeOOC,

С

White solid, $[\alpha]_D^{20} = -8.0$ (*c* 1.28, DCM), 56 % yield, 4.9:1 dr, > 99 % ee; HPLC: Chiralcel AD-H column, hexane/i-PrOH = 85/15, flow rate 1.0 mL/min, UV detection at 220 nm, $t_{major} = 5.6$ min, $t_{minor} = 5.0$ min; ¹H NMR (CDCl₃, 300 MHz) δ 0.80 (t, J = 7.1, 3H), 1.61 (s, 9H), 3.82-

3.96 (m, 5H), 4.19 (s, 1H), 7.09-7.10 (m, 1H), 7.32-7.40 (m, 4H), 7.56 (d, J = 6.9 Hz, 2H), 7.62-7.65 (m, 1H), 7.92-7.97 (m, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 13.4, 28.0, 53.4, 61.4, 62.7, 70.3, 85.3, 87.9, 114.3 (d, J = 26.0 Hz, 1C), 116.1(d, J = 7.7 Hz, 1C), 116.4, 125.7 (d, J = 9.0 Hz, 1C), 126.8, 128.0 (d, J = 28.8 Hz , 1C), 135.8, 135.9, 141.4, 148.7, 160.0 (d, J = 242.9 Hz, 1C), 161.4, 167.9, 171.1, 172.8; HRMS (ESI) Calcd. for C27H27FN2O7 [M+H]⁺: 511.1875, Found: 511.1861; IR (KBr) ν 3452.9, 2982.9, 1762.3, 1733.3, 1481.3, 1369.3, 1305.7, 1290.1, 1147.9, 835.5 cm⁻¹.

(3R,4'S,5'S)-1-tert-butyl 4'-ethyl 5'-methyl 5-chloro-2-oxo-5'-phenyl-4',5'dihydrospiro[indoline-3,3'-pyrrole]-1,4',5'-tricarboxylate (50)

White solid, $[\alpha]_D^{20} = +44.0$ (*c* 0.21, DCM), 58 % yield, 4.5:1 dr, 99 % ee; HPLC: Chiralcel AD-H column, hexane/i-PrOH = 85/15, flow rate 1.0 mL/min, UV detection at 220 nm, $t_{major} = 6.7$ min, $t_{minor} = 5.6$ min; ¹H NMR (CDCl₃, 300 MHz) δ 0.81(t, J = 7.2 Hz, 3H), 1.61(s, 9H),

3.80-3.98 (m, 5H), 4.17 (s, 1H), 7.29-7.39 (m, 5H), 7.56 (d, J = 7.4 Hz, 2H), 7.81 (s, 1H), 7.91 (d, J = 8.7 Hz, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 13.4, 28.0, 53.3, 61.4, 62.8, 70.1, 85.5, 88.0, 116.1, 125.7, 126.8, 126.9, 127.9, 128.2, 129.7, 130.6, 138.5, 141.5, 148.6, 161.3, 167.8, 170.9, 172.5; HRMS (ESI) Calcd. for C27H27CIN2O7 [M+H]⁺: 527.1580, Found: 527.1553; IR (KBr) ν 3458.6, 2981.8, 1765.6, 1732.4, 1471.1, 1337.2, 1290.5, 1261.9, 1149.7, 835.3 cm⁻¹.

(3R,4'S,5'S)-1-tert-butyl 4'-ethyl 5'-methyl 5-bromo-2-oxo-5'-phenyl-4',5'dihydrospiro[indoline-3,3'-pyrrole]-1,4',5'-tricarboxylate (5p)



White solid, $[\alpha]_D^{20} = +51$ (*c* 0.15, DCM), 50 % yield, 3.9:1 dr, > 99 % ee; HPLC: Chiralcel AD-H column, hexane/i-PrOH = 85/15, flow rate 1.0 mL/min, UV detection at 220 nm, $t_{major} = 7.4$ min, $t_{minor} = 6.1$ min; ¹H NMR (CDCl₃, 300 MHz) δ 0.81 (d, J = 7.1 Hz, 3H),

1.61 (s, 9H), 3.79-3.99 (m, 5H), 4.17 (s, 1H), 7.29-7.39 (m, 4H), 7.51-7.57 (m, 3H), 7.85 (d, J = 8.7 Hz, 1H), 7.93 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 13.4, 28.0, 53.4, 61.4, 62.8, 70.0, 85.5, 88.0, 116.5, 118.0, 126.0, 126.8, 127.9, 128.2, 129.6, 132.6, 139.0, 141.5, 148.6, 161.3, 167.8, 170.8, 172.4; HRMS (ESI) Calcd. for C27H27BrN2O7 [M+H]⁺: 571.1074, Found: 571.1062; IR (KBr) v 3373.4, 2981.0, 1765.6, 1732.3, 1468.1, 1337.3, 1291.1, 1151.4, 833.2, 702.6 cm⁻¹.

(3R,4'S,5'S)-1-tert-butyl 4'-ethyl 5'-methyl 5-methyl-2-oxo-5'-phenyl-4',5'dihydrospiro[indoline-3,3'-pyrrole]-1,4',5'-tricarboxylate (5q)



MeOOC

MeO

White solid, $[\alpha]_D^{20} = +20.0$ (*c* 0.80, DCM), 50 % yield, 2.0:1 dr, 98 % ee; HPLC: Chiralcel AD-H column, hexane/i-PrOH = 85/15, flow rate 1.0 mL/min, UV detection at 220 nm, $t_{major} = 6.4$ min, $t_{minor} = 5.6$ min; ¹H NMR (CDCl₃, 300 MHz) δ 0.75 (t, J = 7.1 Hz, 3H), 1.61 (s, 9H),

2.36 (s, 3H), 3.76-3.90 (m, 5H), 4.19 (s, 1H), 7.19 (d, J = 8.1 Hz, 1H), 7.31-7.39 (m, 4H), 7.53-7.58 (m, 3H), 7.80 (d, J = 8.3 Hz, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 13.3, 21.2, 28.0, 53.1, 61.1, 62.7, 70.4, 84.9, 87.6, 114.7, 123.7, 126.8, 127.0, 127.7, 128.2, 130.1, 134.6, 137.5, 141.8, 148.8, 162.0, 168.1, 171.1, 173.2; HRMS (ESI) Calcd. for C28H30N2O7 [M+H]⁺: 507.2126, Found: 507.2119; IR (KBr) v 3453.9, 2956.8, 1760.0, 1731.9, 1491.0, 1367.9, 1258.6, 1197.8, 1137.4, 830.8 cm⁻¹.

(3R,4'S,5'S)-1-tert-butyl 4'-ethyl 5'-methyl 5-methoxy-2-oxo-5'-phenyl-4',5'dihydrospiro[indoline-3,3'-pyrrole]-1,4',5'-tricarboxylate (5r)

White solid, $[\alpha]_D^{20} = +21.3$ (*c* 0.70, DCM), 45 % yield, 2.3:1 dr, > 99 % ee; HPLC: Chiralcel AD-H column, hexane/i-PrOH = 85/15, flow rate 1.0 mL/min, UV detection at 220 nm, $t_{major} = 7.8$ min, $t_{minor} = 6.7$ min; ¹H NMR (CDCl₃, 300 MHz) δ 0.77 (t, J = 7.1 Hz, 3H), 1.61 (s,

9H), 3.77-3.91 (m, 8H), 4.19 (s, 1H), 6.90 (dd, $J_I = 2.7$ Hz, $J_2 = 8.9$ Hz, 1H), 7.31-7.38 (m, 4H), 7.41-7.46 (m, 1H), 7.56 (d, J = 6.9 Hz, 2H), 7.84 (d, J = 8.9 Hz, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 13.4, 28.0, 53.2, 55.7, 61.2, 62.8, 70.7, 84.8, 87.7, 112.1, 115.4, 115.8, 125.0, 126.9, 127.7, 128.2, 133.2, 141.8, 148.9, 157.3, 161.9, 168.1, 171.2, 173.1; HRMS (ESI) Calcd. for C28H30N2O8 [M+Na]⁺: 523.2075, Found: 523.2065; IR (KBr) v 3452.4, 2981.6, 1759.9, 1731.6, 1485.9, 1293.1, 1254.8, 1201.3, 1153.1, 702.0 cm⁻¹.

(3R,4'S,5'S)-1-tert-butyl 4'-ethyl 5'-methyl 6-chloro-2-oxo-5'-phenyl-4',5'dihydrospiro[indoline-3,3'-pyrrole]-1,4',5'-tricarboxylate (5s)



White solid, $[\alpha]_D^{20} = +7.2$ (*c* 0.93, DCM), 51 % yield, 4.1:1 dr, 98 % ee; HPLC: Chiralcel AD-H column, hexane/i-PrOH = 85/15, flow rate 1.0 mL/min, UV detection at 220 nm, $t_{major} = 6.4$ min, $t_{minor} = 5.1$ min; ¹H NMR (CDCl₃, 300 MHz) δ 0.82 (t, *J* = 7.1 Hz, 3H), 1.62 (s, 9H),

3.78 (s, 3H), 3.80-3.93 (m, 2H), 4.16 (s, 1H), 7.19 (dd, $J_1 = 2.0$ Hz, $J_2 = 8.3$ Hz, 1H), 7.32-7.39 (m, 4H), 7.54-7.58 (m, 2H), 7.74 (d, J = 8.3 Hz, 1H), 8.03 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 13.4, 27.9, 53.4, 61.4, 62.7, 69.9, 85.6, 87.8, 115.6, 122.2, 125.1, 126.8, 127.6, 127.8, 128.2, 135.7, 140.7, 141.4, 148.5, 161.3, 167.9, 171.3, 172.7; HRMS (ESI) Calcd. for C27H27CIN2O7 [M+H]⁺: 527.1580, Found: 527.1562; IR (KBr) v 3368.4, 2981.9, 1766.1, 1736.3, 1371.2, 1343.9, 1288.1, 1252.7, 1149.7, 701.4 cm⁻¹.

(3R,4'S,5'S)-1-tert-butyl 4'-ethyl 5'-methyl 6-bromo-2-oxo-5'-phenyl-4',5'dihydrospiro[indoline-3,3'-pyrrole]-1,4',5'-tricarboxylate (5t)



White solid, $[\alpha]_D^{20} = +11.2$ (*c* 1.08, DCM), 55 % yield, 4.0:1 dr, 99 % ee; HPLC: Chiralcel AD-H column, hexane/i-PrOH = 85/15, flow rate 1.0 mL/min, UV detection at 220 nm, $t_{major} = 5.3$ min, $t_{minor} = 6.6$ min; ¹H NMR (CDCl₃, 300 MHz) δ 0.82 (t, *J* = 7.1 Hz, 3H), 1.62 (s, 9H),

3.80 (s, 3H), 3.82-3.93 (m, 2H), 4.16 (s, 1H), 7.29-7.40 (m, 5H), 7.54-7.57 (m, 2H), 7.68 (d, J = 8.2 Hz, 1H), 8.18 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 13.4, 27.9, 53.4, 61.4, 62.7, 70.0, 85.6, 87.9, 118.4, 122.8, 123.6, 126.8, 126.8, 127.9, 128.1, 128.2, 140.8, 141.4, 148.5, 161.2, 167.9, 171.3, 172.6; HRMS (ESI) Calcd. for C27 H27BrN2O7 [M+Ha]⁺: 571.1074, Found: 571.1072; IR (KBr) v 3456.7, 2984.1, 1766.6, 1736.7, 1479.1, 1372.1, 1342.7, 1286.6, 1253.5, 793.1 cm⁻¹.

(3R,4'S,5'S)-1-tert-butyl 4',5'-dimethyl 2-oxo-5'-phenyl-4',5'- dihydrospiro [indoline-3,3'-pyrrole]- 1,4',5'-tricarboxylate (5u)

MeOOC, Ph MeOOC, N MeOO, N MeOO, N MeOO, N MeOO, N MeOO, N MeO, N

(3R,4'S,5'S)-4'-benzyl 1-tert-butyl 5'-methyl 2-oxo-5'-phenyl-4',5'-dihydrospiro [indoline-3,3'-pyrrole]-1,4',5'-tricarboxylate (5v)



White solid, $[\alpha]_D^{20} = -16.1$ (*c* 0.71, DCM), 44 % yield, 2.4:1 dr, > 99 % ee; HPLC: Chiralcel AD-H column, hexane/i-PrOH = 85/15, flow rate 1.0 mL/min, UV detection at 220 nm, $t_{major} = 7.8$ min, $t_{minor} = 5.4$ min; ¹H NMR (CDCl₃, 300 MHz) δ 1.58 (s, 9H), 3.79 (s, 3H), 4.25 (s,

1H), 4.65 (d, J = 11.9 Hz, 1H), 4.84 (d, J = 11.9 Hz, 1H), 6.88 (d, J = 6.8 Hz, 2H) 7.16-7.25 (m, 4H), 7.28-7.36 (m, 5H), 7.55 (d, J = 6.9 Hz, 2H), 7.74 (d, J = 7.6 Hz, 1H), 7.86 (d, J = 8.2 Hz, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 27.9, 53.3, 62.6, 67.4, 70.3, 84.9, 87.8, 115.1, 123.5, 125.1, 126.4, 126.8, 127.8, 128.1, 128.2, 128.3, 128.4, 129.8, 134.3, 139.8, 141.6, 148.6, 161.9, 168.0, 171.2, 172.9; HRMS (ESI) Calcd. for C32H30N2O7 [M+H]⁺: 555.2126, Found: 555.2109; IR (KBr) v 3457.6, 2989.1, 1758.1, 1737.6, 1497.6, 1344.3, 1255.8, 1173.5, 755.0, 697.6 cm⁻¹.

(3R,4'S,5'S)-1,4'-di-tert-butyl 5'-methyl 2-oxo-5'- phenyl-4',5'- dihydrospiro [indoline-3,3'-pyrrole]-1,4',5'-tricarboxylate (5w)



White solid, $[\alpha]_D^{20} = -35.3$ (*c* 0.83, DCM), 50 % yield, 1.9:1 dr, > 99 % ee; HPLC: Chiralcel AD-H column, hexane/i-PrOH = 85/15, flow rate 1.0 mL/min, UV detection at 220 nm, $t_{major} = 4.2$ min, $t_{minor} = 5.2$ min; ¹H NMR (CDCl₃, 300 MHz) δ 1.01 (s, 9H), 1.61 (s, 9H),

3.81 (s, 3H), 4.14 (s, 1H), 7.21-7.43 (m, 6H), 7.56 (d, J = 7.0, 2H), 7.93 (s, 2H); ¹³C NMR (CDCl₃, 75 MHz) δ 27.2, 27.9, 53.2, 64.1, 70.3, 82.3, 84.9, 87.0, 114.9, 124.3, 125.1, 126.8, 126.9, 127.6, 128.1, 129.7, 140.2, 142.1, 148.8, 161.9, 166.9, 171.3, 173.5; HRMS (ESI) Calcd. for C29H32N2O7 [M+Na]⁺: 543.2102, Found: 543.2089; IR (KBr) v 3445.4, 2958.8, 1758.8, 1731.5, 1478.0, 1370.6, 1344.8, 1253.5, 1149.6, 747.8 cm⁻¹.

(3R,4'S,5'S)-1-tert-butyl 4',5'-diethyl 5-methyl-2-oxo-5'-phenyl-4',5'dihydrospiro [indoline-3,3'-pyrrole]-1,4',5'-tricarboxylate (5x)

70.3, 84.8, 87.8, 114.7, 123.8, 126.8, 126.9, 127.6, 128.1, 130.1, 134.6, 137.5, 142.0, 148.8, 161.9, 168.0, 170.5, 173.2; HRMS (ESI) Calcd. for C29H32N2O7 [M+H]⁺: 521.2282, Found: 521.2274; IR (KBr) *v* 3444.8, 2980.3, 1758.7, 1728.4, 1492.4, 1320.6, 1292.2, 1198.3, 1138.5, 830.6 cm⁻¹.

(3R,4'S,5'S)-1-tert-butyl 4',5'-diethyl 5-chloro-2-oxo- 5'-phenyl- 4',5'dihydrospiro[indoline-3,3'-pyrrole]-1,4',5'-tricarboxylate (5y)



White solid, $[\alpha]_D^{20} = +44.0$ (*c* 0.31, DCM), 62 % yield, 5.1:1 dr, 97 % ee; HPLC: Chiralcel AD-H column, hexane/i-PrOH = 85/15, flow rate 1.0 mL/min, UV detection at 220 nm, $t_{major} = 6.2$ min, $t_{minor} = 5.4$ min; 1H NMR (CDCl3, 300 MHz) δ 0.82 (t, J = 7.1 Hz, 3H),

1.30 (t, J = 7.1 Hz, 3H), 1.61 (s, 9H), 3.81-3.99 (m, 2H), 4.16 (s, 1H), 4.27-4.37 (m, 2H), 7.29-7.39 (m, 5H), 7.55 (d, J = 7.1 Hz, 2H), 7.81 (s, 1H), 7.91 (d, J = 8.7 Hz, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 13.4, 13.9, 27.9, 61.3, 62.7, 70.0, 85.4, 88.1, 116.1, 125.8, 126.7, 126.8, 127.8, 128.1, 129.6, 130.5, 138.4, 141.6, 148.6, 161.3, 167.7, 170.3, 172.5; HRMS (ESI) Calcd. for C28H29CIN2O7 [M+H]⁺: 541.1736, Found: 541.1732; IR (KBr) v 3446.5, 2980.1, 1764.1, 1724.3, 1338.2, 1289.5, 1259.4, 1185.1, 1150.2, 836.5 cm⁻¹.

5. Depretection of [3+2] cycloadduct



Procedure for deprotection of 5m: TFA (0.4 mL) was added to a solution of **5m** (80 mg, 99% ee) in DCM (0.6 mL) and stirred for 4h at room temperature, then the reaction mixture was poured into saturated NaHCO₃ aq. and extracted with CH₂Cl₂. Organic layer was dried over anhydrous Na₂SO₄, concentrated under vacuum and purified by flash column chromatography on silica gel to give the white solid **9** in 52 % yield, 82 % ee.

(3R,4'S,5'S)-4'-ethyl 5'-methyl 2-oxo-5'-phenyl-4',5'-dihydrospiro [indoline- 3,3'pyrrole]-4',5'-dicarboxylate (9)

MeOOC, Ph EtOOC, N H White solid, 52 % yield; 99 % ee; HPLC: Chiralcel AD-H column, hexane/i-PrOH = 50/50, flow rate 0.6 mL/min, UV detection at 220 nm, hexane/i-PrOH = 50/50, flow rate 0.6 mL/min, UV detection at 220 nm, $t_{major} = 15.8 \text{ min}, t_{minor} = 7.3 \text{ min}; {}^{1}\text{H} \text{ NMR} (\text{CDCl}_{3}, 300 \text{ MHz}) \delta 0.72 (t,$ J = 7.1 Hz, 3H), 3.76-3.93 (m, 5H), 4.17 (s, 1H), 6.86 (d, J = 7.6 Hz, $1H), 7.07 (t, J = 7.6 Hz, 1H), 7.24-7.29 (m, 1H), 7.32-7.42 (m, 4H), 7.64 (d, J = 7.1 Hz, 2H), 7.68(d, J = 7.5 Hz, 1H), 8.76(s, 1H); {}^{13}\text{C} \text{ NMR} (\text{CDCl}_{3}, 75 \text{ MHz}) \delta 13.4,$ 53.3, 61.1, 61.5, 70.1, 87.8, 109.9, 123.3, 125.2, 126.9, 127.1, 127.7, 128.2, 129.6,140.9, 141.9, 162.7, 168.5, 171.4, 176.2; HRMS (ESI) Calcd. for C22H20N2O5[M+H]⁺: 393.1445, Found: 393.1446.

6. Controlled syntheses of enantio- and diastereomers.

we could access four stereoisomers by changing N-protecting groups and catalysts. Under the optimized reaction condition, catalyst **2b**, the pseudo-enantiomer of **2a**, could promoted the cycloaddtion reaction smoothly, affording the desired enantiomers in a high level of enantiocontrol.



7. Control experiment for testing the effect of N-protecting group on the diasteroselectivity and proposed mechanism.

To investigate the origin of diastereochemical switch, a variety of N-protecting groups were introduced to methyleneindolinones as shown in Scheme 3. We find that N-acetyl group provides anti- product with the same stereochemistry as Nphenylamide group (10a vs 5a), indicating that N-H bonding on phenylamide group isn't the essential factor for determining the diasteroselectivity. In contrast, insertion of an oxygen atom to acetyl reverses the diastereoselectivity (syn-10b vs anti-10a), revealing the oxygen of the alkoxycarbonyl group may play a key role on diastereoselection switch. Steric hindrance of N-protecting groups might not predominate the diasteroselectivity switch because phenylamide group has a semblable phenoxycarbonyl while size as group producing contrary diastereoselectivity (5a vs 10d) and also propionyl group leads to different diastereoselectivity compared to methoxycarbonyl group notwithstanding they have analogical steric hindrance (10e vs 10b). Therefore, on the basis of the analysis above, we hypothesize that electronic effect of oxygen atom on alkoxycarbonyl - or phenoxycarbonyl protecting group rather than steric hindrance effect may play a crucial role in determining diastereochemical switch.



Scheme 3. Control experiment for testing the effect of N-protecting group

A plausible mechanism is proposed in Figure 4. The reaction is initiated through enolization of isocyanoesters by deprotonation at its α -carbon atom by tertiary amine moiety of catalyst, and electron-poor methyleneindolinone is activated by hydrogen-

binding interaction between carbonyl group in the indolinone and thiourea moiety of catalyst. The Re face of methyleneindolinone is approached by in situ generated enolate, and synchronously proton transfer occurs in the conjugated addition step, and subsequent intramolecular cyclization leads to product. The protecting group induced switch of disatereoselectivity can be explained by transition states TS1-TS3. When using N-phenylamide or N-acetyl protecting group, a thermodynamically controlled stable anti- product is generated through TS1. However, when N-alkoxycarbonyl or phenoxycarbonyl is employed, the [3+2] cycloaddition reaction takes place in a kinetically controlled manner and provided syn- products through TS2 because TS3 is disfavored for the electron-repulsion between N-carboxylic esters moieties and electron-rich enolate. The highly asymmetric induction arises from hydrogen-binding interaction between catalyst and both of methyleneindolinone and enolized isocyanoester.



Figure 4. Proposed Mechanism.

Procedure for the synthesis of 10a-e

Methyleneindolinones **3** (0.2 mmol) and Isocyanoesters **4a** (0.3 mmol) were dissolved in 1.0 mL CHCl₃, and 4 Å MS (200 mg) was added. When the mixture was cooled to -20 °C, catalyst **2a** (10 mol%) was added. After stirred for the indicated time, the reaction mixture was directly subjected to flash column chromatography on silica gel (petroleum ether / ethyl acetate) to afford the pure products **10**.

(3R,4'S,5'R)-4'-ethyl 5'-methyl 1-acetyl-2-oxo-5'-phenyl-4',5'-dihydrospiro [indoline - 3,3'-pyrrole]-4',5'-dicarboxylate (10a)

^{Ph, COOMe} ^{EtOOC} White solid, $[\alpha]_D^{20} = -87.2$ (*c* 0.52, DCM), 53 % yield, anti/syn 7.0:1, 96 % ee; HPLC: Chiralcel AD-H column, hexane/i-PrOH = 85/15, flow rate 1.0 mL/min, UV detection at 220 nm, $t_{major} = 12.2$ min, $t_{minor} = 17.2$ min; ¹H NMR (CDCl₃, 300 MHz) δ 0.76 (t, J = 7.1

Hz, 3H), 2.68 (s, 3H), 3.52-3.64 (m, 2H), 3.81 (s, 3H), 4.76 (s, 1H), 7.11-7.18 (m, 2H), 7.32-7.41 (m, 4H), 7.52 (s, 1H), 7.62-7.65 (m, 2H), 8.25 (d, J = 8.2 Hz, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 13.4, 26.7, 53.5, 60.3, 60.8, 68.9, 89.2, 116.6, 122.8, 125.3, 126.2, 126.3, 128.2, 128.3, 130.3, 138.5, 140.8, 162.3, 167.0, 170.4, 171.8, 174.1; HRMS (ESI) Calcd. for C24H22N2O6 [M+H]⁺: 435.1551, Found: 435.1551; IR (KBr) ν 3431.4, 2949.9, 1749.5, 1732.1, 1464.6, 1271.2, 1222.9, 1177.7, 1020.8, 777.6 cm⁻¹.

(3R,4'S,5'S)-4'-ethyl 1,5'-dimethyl 2-oxo-5'-phenyl-4',5'-dihydrospiro [indoline-3,3'-pyrrole]-1,4',5'-tricarboxylate (10b)

(3R,4'S,5'S)-1-benzyl 4'-ethyl 5'-methyl 2-oxo-5'-phenyl-4',5'dihydrospiro[indoline-3,3'-pyrrole]-1,4',5'-tricarboxylate (10c)

(3R,4'S,5'S)-4'-ethyl 5'-methyl 1-phenyl 2-oxo-5'-phenyl-4',5'- dihydrospiro [indoline-3,3'-pyrrole] -1,4',5'-tricarboxylate (10d)

MeOOC. Ph EtOOC. Ph EtOOC. N N EtOOC. N EtOOC

(3R,4'S,5'R)-4'-ethyl 5'-methyl 2-oxo-5'-phenyl-1-propionyl-4',5'- dihydrospiro [indoline-3,3'-pyrrole]-4',5'-dicarboxylate (10e)



White solid, 52 % yield, anti/syn 10.0:1, 98 % ee; HPLC: Chiralcel AD-H column, hexane/i-PrOH = 85/15, flow rate 1.0 mL/min, UV detection at 220 nm, $t_{major} = 10.1$ min, $t_{minor} = 17.3$ min; ¹H NMR (CDCl₃, 300 MHz) δ 0.75 (t, J = 7.2 Hz, 3H), δ 1.24 (t, J = 7.2 Hz, 3H), 3.02-3.12 (m, 2H), 3.51-3.63 (m, 2H), 3.81 (s, 3H), 4.74 (s, 1H),

7.08-7.17 (m, 2H), 7.30-7.40 (m, 4H), 7.52 (s, 1H), 7.63 (d, J = 6.9 Hz, 2H), 8.27 (d, J = 8.3 Hz, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 8.2, 13.4, 32.0, 53.2, 60.3, 60.8, 68.9, 89.1, 116.6, 122.8, 125.2, 126.2, 126.3, 128.2, 128.3, 130.3, 138.5, 141.0, 162.4, 167.1, 171.8, 174.0, 174.5; HRMS (ESI) Calcd. for C25H24N2O6 [M+Na]⁺: 471.1527, Found: 471.1527; IR (KBr) v 3411.3, 2981.7, 1754.9, 1734.9, 1464.1, 1264.1, 1181.2, 1068.8, 1025.2, 762.2 cm⁻¹.

8. Crystal data for 7, 5p and 5m



Crystal data and structure refinement for 7: (CDCC number: CCDC 849672)

Identification code	7
Empirical formula	C22 H21CIN2O5
Formula weight	428.86
Temperature	100(2) K
Wavelength	0.71073 A
Crystal system, space group	Monoclinic, P 21
Unit cell dimensions	a = 12.6866(15) A alpha = 90 deg.
	b = 5.7581(7) A beta = 113.145(2) deg.
	c = 14.9160(18) A gamma = 90 deg.
Volume	1001.9(2) A^3
Z, Calculated density	2, 1.422 Mg/m^3
Absorption coefficient	0.229 mm^-1
F(000)	448
Crystal size	0.80 x 0.19 x 0.06 mm
Theta range for data collection	1.48 to 30.08 deg.
Limiting indices	-17<=h<=17, -7<=k<=8, -21<=l<=20
Reflections collected / unique	10651 / 5461 [R(int) = 0.0226]
Completeness to theta $= 30.08$	95.8 %
Absorption correction	Semi-empirical from equivalents
Max. and min. transmission	0.9864 and 0.8382
Refinement method	Full-matrix least-squares on F^2
Data / restraints / parameters	5461 / 1 / 273
Goodness-of-fit on F ²	1.051
Final R indices [I>2sigma(I)]	R1 = 0.0338, $wR2 = 0.0860$
R indices (all data)	R1 = 0.0366, wR2 = 0.0878
Absolute structure parameter	0.00(5)
Largest diff. peak and hole	0.535 and -0.629 e.A^-3



Crystal data and structure refinement for 5P: (CDCC number: CCDC 849673)

Identification code	5P
Empirical formula	C27 H27BrN2O7
Formula weight	571.42
Temperature	100(2) K
Wavelength	0.71073 A
Crystal system, space group	Orthorhombic, P 21 21 21
Unit cell dimensions	a = 11.9894(7) A alpha = 90 deg.
	b = 13.0968(8) A beta = 90 deg.
	c = 17.2527(10) A gamma = 90 deg.
Volume	2709.1(3) A^3
Z, Calculated density	4, 1.401 Mg/m^3
Absorption coefficient	1.564 mm^-1
F(000)	1176
Crystal size	0.35 x 0.32 x 0.25 mm
Theta range for data collection	1.95 to 30.03 deg.
Limiting indices	-16<=h<=16, -18<=k<=15, -24<=l<=24
Reflections collected / unique	28898 / 7693 [R(int) = 0.0300]
Completeness to theta $= 30.03$	99.1 %
Absorption correction	Semi-empirical from equivalents
Max. and min. transmission	0.6958 and 0.6105
Refinement method	Full-matrix least-squares on F ²
Data / restraints / parameters	7693 / 0 / 340
Goodness-of-fit on F^2	0.994
Final R indices [I>2sigma(I)]	R1 = 0.0224, wR2 = 0.0519
R indices (all data)	R1 = 0.0273, $wR2 = 0.0529$
Absolute structure parameter	0.006(4)
Extinction coefficient	0.0004(2)
Largest diff. peak and hole	0.342 and -0.232 e.A^-3



Crystal data and structure refinement for 5m: (CDCC number: CCDC 849674)

Identification code	5m
Empirical formula	C27 H28N2O7
Formula weight	492.51
Temperature	100(2) K
Wavelength	1.54178 A
Crystal system, space group	Orthorhombic, P 21 21 21
Unit cell dimensions	a = 12.0989(2) A alpha = 90 deg.
	b = 12.7731(2) A beta = 90 deg.
	c = 16.3369(3) A gamma = 90 deg.
Volume	2524.71(7) A^3
Z, Calculated density	4, 1.296 Mg/m^3
Absorption coefficient	0.779 mm^-1
F(000)	1040
Crystal size	0.88 x 0.55 x 0.50 mm
Theta range for data collection	5.42 to 69.52 deg.
Limiting indices	9<=h<=14, -15<=k<=14, -19<=l<=19
Reflections collected / unique	11751 / 4463 [R(int) = 0.0289]
Completeness to theta = 69.52	96.7 %
Absorption correction	None
Refinement method	Full-matrix least-squares on F ²
Data / restraints / parameters	4463 / 0 / 331
Goodness-of-fit on F ²	1.168
Final R indices [I>2sigma(I)]	R1 = 0.0326, $wR2 = 0.0844$
R indices (all data)	R1 = 0.0326, $wR2 = 0.0844$
Absolute structure parameter	0.11(13)
Extinction coefficient	0.0116(5)
Largest diff. peak and hole	0.379 and -0.289 e.A^-3

9. NMR spectra








































S41









Electronic Supplementary Material (ESI) for Chemical Communications This journal is The Royal Society of Chemistry 2012













S51













































11. HPLC chromatograms










Total



84824.807 5781936.297

100.0000

























































































```
Electronic Supplementary Material (ESI) for Chemical Communications This journal is \textcircled{C} The Royal Society of Chemistry 2012
```







